A Cash-Pay Telehealth Triplicate: Oxycodone, Alprazolam, and a Prescriber Who "Doesn't Take Calls"
A Virginia pharmacy receives three electronic prescriptions for a 26-year-old: oxycodone 30 mg #90, alprazolam 2 mg #90, and promethazine-codeine #240, all from the same out-of-state telehealth prescriber, all cash-pay, all written the same day. The patient's address is in Virginia, but the pharmacy's profile shows a different address two hours away and a phone number in another area code. The Virginia Prescription Monitoring Program shows five pharmacies and four prescribers in the last 60 days, plus an active buprenorphine prescription. The pharmacist calls the prescriber's office; the staff member says the prescriber "doesn't take pharmacy calls" and that the prescriptions should be filled as written. The prescriber holds a DEA registration, but the pharmacist cannot confirm Virginia licensure.
1. Does the pharmacist have authority to refuse to fill? Walk through the legal basis.
Read the worked answer
Yes - refusal is not just permitted, it is the expected exercise of corresponding responsibility.
Legal scaffolding:
- Corresponding responsibility (21 CFR 1306.04): the pharmacist shares responsibility for the legitimacy of a controlled-substance prescription. A pharmacist who fills with unresolved red flags has violated the regulation even if the prescription is technically genuine.
- Virginia's bona fide practitioner-patient relationship requirement: prescribing, including via telehealth, must rest on an actual practitioner-patient relationship established through a documented encounter. A questionnaire-and-credit-card encounter does not satisfy it, and the pharmacist may not fill a controlled-substance prescription lacking that foundation.
- PMP data is affirmative evidence, not background noise. Four prescribers, five pharmacies, and an active buprenorphine prescription in 60 days with concurrent opioid and benzodiazepine is the classic high-risk constellation.
Red flags present: cash pay, distant/conflicting addresses, opioid + benzodiazepine + codeine combination, high quantities, single-day triple prescribing, telehealth-only prescriber, prescriber unreachable, patient-level PMP pattern.
Conclusion: do not fill. Return the paper or annotate the electronic prescription as not filled and notify the prescriber in writing.
2. What must be verified about the out-of-state prescriber before any controlled substance could be dispensed, and what do you do if verification fails?
Read the worked answer
Verify authority, not just a DEA number.
- A DEA registration is state-specific and location-specific. An active registration in another state does not, by itself, establish that the prescriber may prescribe for a Virginia patient. Confirm the prescriber's Virginia licensure and DEA registration (or a recognized exception) using the Board's license lookup and DEA's registration verification, and document what you found and when.
- Confirm the prescriber is registered to prescribe Schedule II (registration tiers differ: II–V vs. III–V).
- Confirm the e-prescribing path is valid for controlled substances: the prescriber's e-prescribing system must be DEA-compliant, and Virginia's electronic prescribing requirements for controlled substances apply, subject to narrow statutory exceptions.
- Query the PMP and record the query.
If verification fails or cannot be completed: the prescription is not dispensable. Do not "hold" it indefinitely as a courtesy; annotate it as not filled, return or void per system capability, notify the prescriber's office in writing of the specific verification needed, and tell the patient plainly what to do next (obtain a prescription from a Virginia-authorized prescriber, or have the prescriber resolve the verification).
3. What documentation and reporting should follow a refusal, and what should the pharmacist avoid saying or doing?
Read the worked answer
Document contemporaneously, neutrally, and completely.
Record: date/time received, prescriber identifiers, the specific red flags, PMP query results, the verification attempts (dates, names, what the office said), the pharmacist's clinical reasoning, the decision, and the patient notification.
Operational steps:
- Return or annotate the prescription; do not fill partially, do not "hold" it for a different shift to decide, and do not delete it from the system.
- Notify the prescriber in writing of the refusal and the reason - this protects the pharmacist and puts the prescriber on notice.
- Consider reporting to the Virginia Board of Pharmacy (complaint process) and, where diversion is suspected, to DEA Diversion; a cluster of patients from one telehealth prescriber is worth a report even if this single prescription is ambiguous.
- Offer the patient a copy/return of the prescription and referral to a Virginia-authorized prescriber or an appropriate treatment resource (including buprenorphine access, given the PMP).
Avoid: accusations of drug-seeking in front of other customers, discussing the PMP with anyone other than the patient or prescriber, telling the patient "we don't fill for that doctor" without explanation, and documenting opinions rather than facts. Refusal is a professional judgment; the record should let another pharmacist reach the same conclusion.